作者: Tsafrir Vanounou , Richard Garfinkle
DOI: 10.1245/S10434-016-5096-4
关键词: Internal medicine 、 Peritoneal Neoplasm 、 Evidence-based medicine 、 Cost effectiveness 、 Surgical oncology 、 Metastasis 、 Hyperthermic intraperitoneal chemotherapy 、 Oncology 、 Colorectal cancer 、 Combined Modality Therapy 、 Medicine 、 Surgery
摘要: Peritoneal spread from colorectal cancer is second only to the liver as a site for metastasis. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) well-established treatment option patients with peritoneal carcinomatosis (PC) of origin. However, due concerns regarding both its clinical benefit high cost, universal adoption standard care limited dissemination has been slow. The purpose this review was clarify utility cost effectiveness CRS-HIPEC in PC using framework value-based medicine, which attempts combine into single quantifiable metric. Our comprehensive outcomes demonstrate that it highly valuable oncologic therapy good use healthcare resources.